Clinical Trial Update: Inhibition of Food Intake in Response to Oral GLP-1 and Peptide YY3-36 [Phase 1, Phase 2]

View source ↗

Summary

This trial update reports completion of Phase 1 and Phase 2 studies evaluating oral GLP-1 and peptide YY3-36 for reducing food intake in obesity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• GLP-1 (glucagon-like peptide-1)
• Peptide YY3-36 (peptide YY3-36)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Anti Obesity Agent | Phase 1, Phase 2 | Status: COMPLETED